Print

TaMoVac II

A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet? With or Without ID Derma Vax? Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique (TaMoVac II)

Trial Details:

II Completed
Karolinska Institutet, US Military HIV Research Program, Swedish Institute for Infectious Disease Control, Muhimbili University of Health and Allied Sciences April 01, 2013
HIVIS-DNA,MVA-CMDR DNA Env A, B and C and Rev B while pool 2 comprised plasmids encoding Gag A, B and RTmut B; Pox gag-pol CM 240, env CM235
HIVIS-DNA DNA
MVA-CMDR Viral Vector - Pox
Tanzania, Mozambique 198
NCT01697007
http://clinicaltrials.gov/ct2/show/NCT01697007?term=hiv+vaccine&lup_s=09%2F09%2F2012&lup_d=30